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Oral Presentations 27amphotericin B therapy (p5 0.08) were not statistically significant.
There was a slight trend towards a higher rate of chronic GVHD in
patients with ES (p 5 0.11). However, after a median follow up of
9.5 years overall survival (48% with ES vs. 50% without ES; p 5
0.53) and transplant related mortality (21% vs. 17%; p 5 0.65)
did not differ between the two groups. Prednisolone (2 mg/kg/d)
was administered in 62% of children with ES.Conclusion: ES pre-
senting with fever, rash, weight gain and pulmonary symptoms
should be recognized as a frequent complication of allogeneic
HSCT after myeloablative conditioning in children. Treatment
withG-CSF and a high nucleated cell count of the graft predisposed
for the development of ES in this study. Overall survival and trans-
plant relatedmortality in this cohort were not affected by the occur-
rence of ES, possibly due to therapeutic intervention with
prednisolone in a high proportion of patients.66
EXCELLENT ENGRAFTMENT AND RAPID IMMUNE RECOVERY IN HAP-
LOIDENTICAL STEM CELL TRANSPLANTATION USING CD3/CD19 DE-
PLETED PERIPHERAL STEM CELL GRAFTS AFTER REDUCED
INTENSITY CONDITIONING
Bader, P.1, Soerensen, J.1, Koehl, U.1, Kreyenberg, H.1, Jarisch, A.1,
Weber, G.1, Sach, G.1, Willasch, A.1, Kuci, S.1, Tonn, T.2, Esser, R.1,
Klingebiel, T.1. 1 JW Goethe University Children’s Hospital, Frankfurt,
Germany; 2 Institut fu¨r Transfusionsmedizin, Frankfurt, Germany.
Transplantation of haploidentical stem cells has become a well
established treatment procedure in many children with malignant
and non malignant diseases. Positive enrichment of stem cells by
anti-CD34 magnetic micro beads provides a graft profoundly de-
pleted of T and B cells facilitating engraftment without inducing se-
vere GVHD. However, despite transplanting ‘‘mega doses’’ (.107/
kgBW) of stem cells, primary graft rejection and delayed immune
recovery associated with increased transplant related mortality re-
mained major obstacles. Grafts after depletion of CD3/CD19 cells
consist of remarkable amounts of effector cells which might help to
improve engraftment and immune reconstitution.
We report the results of our pilot study including 29 children and
adolescents (ALL, n5 10; AML, n5 3; RMA, n5 10; aplastic anae-
mia, n5 1, MDS, n5 2 and NBL/HB n5 2). All patients received
CD3/CD19 depleted peripheral stem cell grafts containing a me-
dian number of 7.46/kgBW CD341 cells. Grafts also contained
NK-cells (median number: 14.36/kgBW), dendritic cells, precursor
T-cells and mono-/granulocytes (median number: 423.46/kgBW).
All patients but two received a reduced conditioning regimen with
FLU-MEL-THIO and short course of OKT-3. All twenty-nine pa-
tients achieved rapid engraftment at day 14 and 156 days, respec-
tively. Immune recovery was excellent with a median time to
achieve more than 100 CD31 and CD41 cells/ml was 61.0 and
63.5 days, respectively. Five/29 patients developed acute GvHD
grade II and grade III (n 5 2). Fourteen out of 29 patients (48%)
are alive and in CR with a median follow-up of 282 days (range:
42–968 days). Two heavily pre-treated patients died due to TRM.
Ten patients died due to relapse of their underlying disease. Two
patients died of Adeno virus infection. In conclusion, haploidentical
transplantation using CD3/CD19 depleted grafts seems to be a fea-
sible strategy to overcome the high risk of graft rejection and to im-
prove immune reconstitution.67
CLINICAL OUTCOMES OF ADOLESCENT PATIENTS UNDERGOING HEMA-
TOPOIETIC STEM CELL TRANSPLANT
Midura, B.2, Lehmann, L.1, Duncan, C.1. 1 Dana-Farber Cancer Insti-
tue, Boston, MA; 2 Children’s Hospital, Boston, Boston, MA.
There is concern that the outcome for adolescent oncology pa-
tients is worse than that of younger patients with the same disease.
The effect of patient age on outcome following pediatric allogeneic
hematopoietic stem cell transplant (HSCT) has not been well de-
scribed. We retrospectively reviewed the medical records of all pe-diatric allogeneicHSCTpatients at our institution between January
1, 2001 and December 31, 2006. We investigated survival, cause of
death, and occurrence of graft-versus-host disease (GVHD) in pa-
tients 15–21 years old at time of HSCT compared with patients
10–14.9 years old at transplant. 127 patients greater than 10 years
old (10–14.9 years 5 73 patients; greater than 15 years 5 54 pa-
tients) were transplanted during the study period. Indications for
HSCT were similar in both groups (see table). 53.4% of patients
in the younger group received unrelated donor (URD) transplants
compared with 48.1% in the older group. A greater percentage of
patients in the younger group received cells from a donor matched
at less than 6 HLA loci (20.5% versus 9.3%). There was no statisti-
cally significant difference in the incidence of chronic GVHD
(younger 42.5%, older 46.2%). Patients greater than 15 years old
had a higher risk of mortality compared to younger patients (odds
ratio5 1.85). Relapse was the cause of death (COD) in 13.7%of pa-
tients in the younger group and 16.7% of patients in the older
group. Transplant related mortality (TRM) was greater in the older
group (younger 16.4%, older 27.8%). Older adolescents had in-
creased toxicity resulting in increased mortality following HSCT
compared to younger adolescents with similar underlying disease
and transplant characteristics. Further study is needed to better un-
derstand these findings and their potential impact on the care of ad-
olescent stem cell transplant patients.
Younger Adolescents Compared with Older Adolescents
Age 10–14.9 Age .15
years (n5 73) years (n5 54)Death 22 (30.1%) 24 (44.4%)
Cause of death: Relapse 10 9
Cause of death: TRM 12 15
Chronic GVHD 31 (42.5%) 25 (46.2%)
Related donor 34 (46.6%) 28 (51.9%)
Source: bone marrow 65 (89%) 51 (94.6%)
Acute lymphoblastic 24 (32.9%) 14 (25.9%)
Acute myelogenous leukemia/
myelodysplasia26 (35.6%) 20 (37%)Chronic myelogenous
leukemia8 (11%) 8 (14.8%)Nonmalignant hematologic
disease9 (12.3%) 10 (18.5%)Other 6 (8.2%) 2 (3.7%)68
GENE THERAPY FOR ADENOSINE DEAMINASE (ADA)-DEFICIENT SE-
VERE COMBINED IMMUNE DEFICIENCY (SCID): COMPARATIVE RE-
SULTS WITH OR WITHOUT PEG-ADA WITHDRAWAL AND
MYELOSUPPRESSIVE CHEMOTHERAPY
Podsakoff, G.1, Engel, B.C.1, Sokolic, R.2, Carbonaro, D.A.1, Muul, L.2,
Garabedian, E.2, Ireland, J.1, Hershfield, M.3, Wayne, A.4, Dunbar, C.5,
Candotti, F.2, Kohn, D.B.1. 1 Childrens Hospital Los Angeles, Los Angeles,
CA; 2 National Institutes of Health, Bethesda, MD; 3 Duke University
Medical Center, Durham, NC; 4 National Institutes of Health, Bethesda,
MD; 5 National Institutes of Health, Bethesda, MD.
In 2001–2002, we treated 4 ADA-SCIDpatients in a gene therapy
(GTx) clinical trial evaluating the efficacy of 2 different retroviral
vectors while continuing enzyme replacement with pegylated bo-
vine ADA (PEG-ADA). No cytoreductive conditioning was used.
All patients have been monitored for 6 years. No treatment-related
SAE occurred. A mild transient elevation in absolute lymphocyte
count (ALC) was seen in 2 patients early post-treatment, however,
no durable immunologic changes were observed. Low levels (0.1–
0.7%) of vector-marked PBMC persist for at least five years in 2 pa-
tients treated at the age of 4–5 years. All patients remain on PEG-
ADA, prophylactic antibiotics and IVIg. In 2004, we revised the
protocol to facilitate engraftment and selective advantage of gene-
corrected cells by withdrawing PEG-ADA and giving busulfan
(75 mg/m2) before GTx. In November 2005, a 1st patient was
treated who developed unexpected prolonged bone marrow (BM)
